<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11782">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953548</url>
  </required_header>
  <id_info>
    <org_study_id>GWEP15100 Pilot Phase</org_study_id>
    <secondary_id>2015-004904-50</secondary_id>
    <nct_id>NCT02953548</nct_id>
  </id_info>
  <brief_title>Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Research Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Research Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase,
      and an open-label extension phase. The pilot phase only will be described in this record. 2
      cohorts of 5 participants will be enrolled sequentially. All participants will receive
      GWP42003-P.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experienced a treatment-emergent adverse event.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants who experienced an adverse event that started, or worsened in severity or seriousness, following the first dose of study drug is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a potentially clinically significant change in clinical laboratory tests.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants with a potentially clinically significant change in clinical laboratory tests is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants with a clinically significant change in ECG is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with a clinically significant change in vital signs.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants with a clinically significant change in vital signs (systolic and diastolic blood pressure, pulse rate, body temperature and respiratory rate) is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of treatment responders.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants who are free of spasms and have resolution of hypsarrhythmia is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who are spasm-free.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants who are free of clinical spasms is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants without hypsarrhythmia.</measure>
    <time_frame>2 weeks</time_frame>
    <description>The number of participants with resolution of hypsarrhythmia is presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Infantile Spasms</condition>
  <arm_group>
    <arm_group_label>GWP42003-P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GWP42003-P</intervention_name>
    <description>Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.</description>
    <arm_group_label>GWP42003-P</arm_group_label>
    <other_name>CBD</other_name>
    <other_name>Cannabidiol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Participant is diagnosed with IS and has failed to respond adequately following
             treatment with 1 or more approved IS therapies.

        Key Exclusion Criteria:

          -  Participant is currently taking or has taken clobazam or any mammalian target of
             rapamycin (mTOR) inhibitor within the 2 weeks prior to the screening visit.

          -  Participant has a QT interval, corrected for heart rate with Bazett's formula (QTcB),
             of 460 msec or greater on ECG.

          -  Participant's caregiver is currently giving or has given recreational or medicinal
             cannabis, or synthetic cannabinoid-based medications, within the 1 month prior to the
             screening visit.

          -  Participant's caregiver is unwilling to abstain from giving the participant
             (including the participant's mother abstaining themselves, if
             breastfeeding)recreational or medicinal cannabis, or synthetic cannabinoid-based
             medications (other than the study drug) during the trial.

          -  Participant has any known or suspected hypersensitivity to cannabinoids or any of the
             excipients of the study drug, such as sesame oil.

          -  Participant has significantly impaired hepatic function at the screening visit.

          -  Participant has received an investigational medicinal product as part of a clinical
             trial within a minimum of 5 half-lives prior to the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>GW Research Medical Information</last_name>
    <phone>+44 (0) 1223 266 800</phone>
    <email>medinfo@gwpharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>November 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GWP42003-P</keyword>
  <keyword>Cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
